Revenues and other income (Tables)

6 Months Ended

Jun. 30, 2020

Total revenues and other income

Schedule of revenues

		Six months ended June 30,
	Over time	2020		2019
		(Euro, in thousands)
Recognition of non-refundable upfront payments and license fees		€	180,711	€	42,113
Gilead collaboration agreement for filgotinib	Ö		67,992		41,069
Gilead collaboration agreement for drug discovery platform	Ö		112,719		—
AbbVie collaboration agreement for CF	Ö		—		1,044
Milestone payments			6,996		33,383
Gilead collaboration agreement for filgotinib	Ö		6,996		10,034
AbbVie collaboration agreement for CF	Ö		—		23,349
Reimbursement income			6,628		11,344
Novartis collaboration agreement for MOR106	Ö		6,659		10,595
AbbVie collaboration agreement for CF	Ö		(31)		749
Other revenues			7,438		4,944
Fee-for-services revenues	Ö		7,369		4,878
Other revenues			69		66
Total revenues		€	201,773	€	91,785

Schedule of current and non-current deferred income

		Total		Gilead collaboration agreement for filgotinib		Gilead collaboration agreement for drug discovery platform (1)		Deferred income related to contracts in our fee-for-service segment		Deferred income related to grants		Other
		(Euro, in thousands)
On January 1, 2020	€	3,000,646	€	780,261	€	2,220,013	€	362	€	—	€	10
Significant financing component (2)		8,728		8,728
Revenue recognition of upfront		(180,711)		(67,992)		(112,719)
Revenue recognition of milestones		(6,996)		(6,996)
Other movements		2,166						(324)		2,500		(10)
On June 30, 2020	€	2,823,833	€	714,001	€	2,107,294	€	38	€	2,500	€	—

(1) The outstanding balance at January 1,2020 and June 30,2020 comprise the issuance liability for subsequent warrant B and the upfront payment allocated to the drug discovery platform.

(2) With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a significant financing component reflecting the time value of money on the estimated recognition period.